Sidewinder Therapeutics raised $100M Series A in 2025 for its conditional activation platform that creates tumor-selective cancer drugs that only become active in the tumor microenvironment, reducing systemic toxicity.
Sidewinder Therapeutics is developing conditionally activated cancer therapeutics — drugs engineered to remain inert in circulation and become pharmacologically active only when they reach the tumor microenvironment. The approach exploits the unique biochemical conditions of solid tumors (acidic pH, hypoxia, tumor-specific proteases) to trigger drug activation, allowing far higher doses to be delivered to tumors with dramatically reduced side effects in healthy tissues.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.